CR20220641A - Compuestos de insulina acilada de acción temporal prolongada - Google Patents

Compuestos de insulina acilada de acción temporal prolongada

Info

Publication number
CR20220641A
CR20220641A CR20220641A CR20220641A CR20220641A CR 20220641 A CR20220641 A CR 20220641A CR 20220641 A CR20220641 A CR 20220641A CR 20220641 A CR20220641 A CR 20220641A CR 20220641 A CR20220641 A CR 20220641A
Authority
CR
Costa Rica
Prior art keywords
compounds
acylated insulin
long
insulin compounds
acting acylated
Prior art date
Application number
CR20220641A
Other languages
English (en)
Inventor
Valdislav Kisselev
David Benjamin Flora
Wen Liu
Francisco Alcides VALENZUELA
Seamus Patrick Brennan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20220641A publication Critical patent/CR20220641A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos descritos en la presente se refieren al tratamiento de la diabetes tipo I y/o tipo II y/o la hiperglucemia. Más particularmente, los compuestos descritos se refieren a compuestos de insulina acilada de acción temporal prolongada que reducen la glucosa en sangre, composiciones farmacéuticas que contienen tales compuestos, usos terapéuticos de tales compuestos y un compuesto intermediario usado para fabricar los compuestos de insulina acilada.
CR20220641A 2020-05-15 2021-05-13 Compuestos de insulina acilada de acción temporal prolongada CR20220641A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025463P 2020-05-15 2020-05-15
PCT/US2021/032144 WO2021231676A1 (en) 2020-05-15 2021-05-13 Extended time action acylated insulin compounds

Publications (1)

Publication Number Publication Date
CR20220641A true CR20220641A (es) 2023-01-19

Family

ID=78524979

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220641A CR20220641A (es) 2020-05-15 2021-05-13 Compuestos de insulina acilada de acción temporal prolongada

Country Status (19)

Country Link
US (1) US20230174609A1 (es)
EP (1) EP4149516A4 (es)
JP (1) JP7456007B2 (es)
KR (1) KR102940858B1 (es)
CN (1) CN115867308B (es)
AU (2) AU2021273262A1 (es)
BR (1) BR112022022885A2 (es)
CA (1) CA3177905A1 (es)
CL (3) CL2022003187A1 (es)
CO (1) CO2022016338A2 (es)
CR (1) CR20220641A (es)
EC (1) ECSP22087958A (es)
IL (1) IL297976B1 (es)
JO (1) JOP20220311A1 (es)
MX (1) MX2022014309A (es)
PE (1) PE20230832A1 (es)
UA (1) UA129395C2 (es)
WO (1) WO2021231676A1 (es)
ZA (1) ZA202212408B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN115947822B (zh) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法
TW202511291A (zh) 2023-09-11 2025-03-16 丹麥商諾佛 儂迪克股份有限公司 抗ｉｌ－６結構域之抗體
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
CN118063589A (zh) * 2024-02-04 2024-05-24 乐普健糖药业(重庆)有限公司 一种超长效胰岛素类似物及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
EA200000453A1 (ru) * 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
WO2009010428A1 (en) * 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
EP2838914B1 (en) * 2012-04-19 2017-06-14 Novo Nordisk A/S Human amylin analogues
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TW201716432A (zh) * 2015-07-06 2017-05-16 諾佛 儂迪克股份有限公司 新穎肽與肽衍生物及其用途
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
PE20201254A1 (es) * 2018-02-27 2020-11-16 Zp Spv 3 K/S Analogos de compstatina y sus usos medicos

Also Published As

Publication number Publication date
UA129395C2 (uk) 2025-04-09
EP4149516A1 (en) 2023-03-22
US20230174609A1 (en) 2023-06-08
IL297976A (en) 2023-01-01
MX2022014309A (es) 2022-12-07
ECSP22087958A (es) 2022-12-30
CL2025000632A1 (es) 2025-06-23
JOP20220311A1 (ar) 2022-11-16
IL297976B1 (en) 2026-04-01
KR20230009499A (ko) 2023-01-17
WO2021231676A1 (en) 2021-11-18
PE20230832A1 (es) 2023-05-19
ZA202212408B (en) 2025-06-25
CO2022016338A2 (es) 2022-11-29
CA3177905A1 (en) 2021-11-18
KR102940858B1 (ko) 2026-03-19
CL2022003187A1 (es) 2023-03-03
EP4149516A4 (en) 2024-11-13
JP2023526069A (ja) 2023-06-20
JP7456007B2 (ja) 2024-03-26
AU2021273262A1 (en) 2022-12-08
BR112022022885A2 (pt) 2022-12-20
CN115867308B (zh) 2025-12-30
AU2025202879A1 (en) 2025-05-15
CL2025000631A1 (es) 2025-07-04
CN115867308A (zh) 2023-03-28

Similar Documents

Publication Publication Date Title
CR20220641A (es) Compuestos de insulina acilada de acción temporal prolongada
PH12019502655A1 (en) Acylated insulin compound
BR112022013009A2 (pt) Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
ZA202406617B (en) Insulin containing pharmaceutical compositions
NO20084919L (no) Oksadiazolidindionforbindelse
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MX2017004614A (es) Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas.
MY152172A (en) Therapeutic agent for diabetes
JOP20230218A1 (ar) مشتقات بيرازولو بيريدين واستخداماتها
CO2022007273A2 (es) Análogos de insulina novedosos y usos de estos
ZA202310748B (en) Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin
MX2020009271A (es) Composiciones y métodos para el tratamiento de la resistencia a la insulina.
MX2026000538A (es) Composiciones farmaceuticas de derivados de la insulina